37 results about "Post menopausal osteoporosis" patented technology

A method for the prevention or treatment of postmenopausal osteoporosis by initiating the treatment with a low dose of an estrogenic compound and increasing the dose of the estrogenic compound after the initiation period.

The invention relates to a traditional Chinese medicine composition capable of increasing estrogen. The traditional Chinese medicine composition is prepared from following bulk drugs: honey bran friedwhite peony root, white poria, cassia twig, radix bupleuri, mint, honey bran fried rhizoma atractylodis, Ligusticum wallichii, peeled peach kernel, honey stirred licorice root, oriental waterplantainrhizome, Chinese angelica, tree peony bark, and rhizoma zingiberis. The invention also provides applications of the traditional Chinese medicine composition. The combination of the traditional Chinese medicine composition is appropriate; the traditional Chinese medicine composition is capable of increasing estrogen under the comprehensive effect of the bulk drugs. The traditional Chinese medicinecomposition can be used for treating estrogen related diseases such as climacteric syndrome and postmenopausal osteoporosis.

The present invention is drawn to methods of repairing lytic bone lesions and tumor growth in an individual. In this regard, the present invention discloses use of a Wnt ligand either alone or in combination with anti-Wnt signaling antagonist therapy. The individuals who might benefit from such method may include but are not limited to the ones with multiple myeloma, osteoporosis, post-menopausal osteoporosis, fractures, metastatic breast cancer or metastatic prostate cancer.

Provided in the present invention is the use of the miR-338 cluster as a marker of postmenopausal osteoporosis. In the present invention, it was found that the miR-338 cluster such as miR-338-3p and / or miR-3065-5p are highly expressed in patients with postmenopausal osteoporosis, and it can be used as a marker of postmenopausal osteoporosis, used for preparing an auxiliary diagnostic kit for postmenopausal osteoporosis, which can specifically detect the expression level of the miR-338 cluster in tissues, and is used for non-invasive and early auxiliary diagnosis of postmenopausal osteoporosis in clinic. In addition, inhibitors of the miR-338 cluster have the efficacy of promoting osteogenesis and can be used for treating or preventing postmenopausal osteoporosis.

The invention relates to a molecular traditional Chinese medicine sustained-release tablet for resisting bone mass loss and a preparation method thereof. The molecular traditional Chinese medicine sustained-release tablet comprises molecular traditional Chinese medicine ingredients and pharmaceutically allowed auxiliary material ingredients, wherein the molecular traditional Chinese medicine components comprise 1-5 parts of specnuezhenide (ligustrum lucidum), 1-5 parts of wedelolactone (eclipta prostrata), 0.5-3 parts of paeoniflorin (peony), 0.5-3 parts of psoralen (psoralea corylifolia), and 1-5 parts of diosgenin (yam) ]; and the auxiliary material ingredients comprise 10-50 parts of sodium alginate, 1-5 parts of carbomer (934) , 10-30 parts of hydroxypropyl methyl cellulose, 10-40 parts of lactose, and 1-5 parts of magnesium stearate. Based on a theory of Chinese medicine and a theory of sustained-release preparations, Chinese medicine pathological features of postmenopausal osteoporosis, and scientific compatibility, the molecular traditional Chinese medicine sustained-release tablet which is safe and reliable, high in bioavailability and significant in curative effect is developed.